Company intelligence / Profile preview

Xsome Biotech

Ownership: Private
Development stage: Other

Overview

Xsome Biotech develops exosome therapeutics and novel drug delivery carriers, with a lead program focused on lung stem cell-derived secretomes for inhaled delivery. Their proprietary ResEV platform enables precise drug targeting to the lung parenchyma, showing several-fold enhancement over liposomes. The company has also pioneered engineered extracellular vesicles for lung regeneration and has explored applications in infectious disease using recombinant SARS-CoV‑2 domains[1][4]. No published clinical results are available.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Exosome-based therapySecretome-based therapyDrug delivery carrier (via exosomes)
Industry: Biotech

Drug pipeline

4 assets

XSO201

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Xsome Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xsome Biotech.

Explore the full profile